

P & T COMMITTEE MEETING

Agenda

January 5, 2016

1:00 pm – 5:00 p.m.

303 E. 17th Avenue, 11th Floor Conference Room, Denver, Colorado

P&T background

Committee member Introductions: openings/new appointments

Vote for new chair and vice chair

Unfinished Business and General Orders

1. Approval of minutes from the October 6, 2015 P&T Meeting
2. Update on Antiherpetics
3. Update on Antiplatelets
4. Update on Antiemetics
5. Update on Fluoroquinolones
6. Update on New Generation Antidepressants
7. Update on Pancreatic enzymes
8. Update on Proton Pump Inhibitors
9. Update on Pulmonary Arterial Hypertension Therapies
10. Update on Targeted Immune Modulators
11. Update on Triptans

New Business

- Update P&T Policy and Procedures with Factual Inaccuracy Policy
- Update from Prior Authorization call center

Drug Classes Up for Review:

- Alzheimer's agents
- Atypical antipsychotics
- Growth hormones
- Insulin
- Intranasal corticosteroids
- Leukotriene modifiers
- Multiple Sclerosis agents
- Ophthalmic allergy

- Sedative/hypnotics (non benzodiazepine)
- Statins and Statin combinations

Each Review will contain:

- Drug class Overview and Agents up for review for each Drug Class
- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

Upcoming Meeting Date: Tuesday, April 5, 2016; 1:00 p.m. – 5:00 p.m.

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Kelli Metz at 303-866-3982 or by email at Kelli.Metz@state.co.us. Written public comments can be submitted to PDLproject@state.co.us or Kelli.Metz@state.co.us and will be distributed to all present P&T Committee Members.